{"transactions":[{"id":767664,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T20:30:08.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":24122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":63920,"source":{"system":"sec-edgar","filing":"0001193125-26-234566","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119312526234566/ownership.xml","form_type":"4"}},{"id":1078290,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-31T15:52:10.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a \"Share\") for (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.77,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0000950170-25-100680","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000095017025100680/ownership.xml","form_type":"4"}},{"id":1111283,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:13:36.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":21500,"derivative":{"exercise_price":6.77,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001562180-25-004788","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218025004788/primarydocument.xml","form_type":"4"}},{"id":1121074,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:58:12.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":4.95,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-25-082456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000095017025082456/ownership.xml","form_type":"4"}},{"id":1121073,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:58:12.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":39798,"source":{"system":"sec-edgar","filing":"0000950170-25-082456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000095017025082456/ownership.xml","form_type":"4"}},{"id":1483195,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:57:48.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":12500,"derivative":{"exercise_price":10.9,"expiration_date":"2034-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-24-004949","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218024004949/primarydocument.xml","form_type":"4"}},{"id":1501728,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T23:44:23.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":10.3,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-24-064830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000095017024064830/ownership.xml","form_type":"4"}},{"id":1501727,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T23:44:23.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":29298,"source":{"system":"sec-edgar","filing":"0000950170-24-064830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000095017024064830/ownership.xml","form_type":"4"}},{"id":1851763,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T20:05:16.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":56.1,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-23-005258","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218023005258/primarydocument.xml","form_type":"4"}},{"id":1874485,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-30T22:46:54.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.72,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-033004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919123033004/doc4.xml","form_type":"4"}},{"id":1874484,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T22:46:54.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":18798,"source":{"system":"sec-edgar","filing":"0001209191-23-033004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919123033004/doc4.xml","form_type":"4"}},{"id":2227263,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:36:06.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":9947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":9947,"derivative":{"exercise_price":31.36,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":9947},"source":{"system":"sec-edgar","filing":"0001562180-22-005206","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218022005206/primarydocument.xml","form_type":"4"}},{"id":2253001,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:39:43.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":7.4,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-032574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919122032574/doc4.xml","form_type":"4"}},{"id":2385018,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-19T00:34:06.000Z","date":"2019-10-29","kind":"purchase","acquired":true,"shares":9798,"price":19,"value":186162.0,"ownership":{"direct":true},"balance_after":9798,"source":{"system":"sec-edgar","filing":"0001209191-22-011484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919122011484/doc4.xml","form_type":"4"}},{"id":2551543,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-04T20:28:00.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":78116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock\noption that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled."}],"balance_after":78116,"derivative":{"exercise_price":2.25,"exercise_date":"2021-10-01","expiration_date":"2031-10-01","underlying":"Common Stock","underlying_shares":78116},"source":{"system":"sec-edgar","filing":"0001878894-21-000003","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000187889421000003/edgar.xml","form_type":"4"}},{"id":2643981,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:44:30.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":51740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock\noption that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled."}],"balance_after":51740,"derivative":{"exercise_price":3.39,"exercise_date":"2021-07-01","expiration_date":"2031-07-01","underlying":"Common Stock","underlying_shares":51740},"source":{"system":"sec-edgar","filing":"0001192482-21-000611","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248221000611/edgar.xml","form_type":"4"}},{"id":2671563,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T20:11:01.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":76.09,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004208","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218021004208/primarydocument.xml","form_type":"4"}},{"id":2698508,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-24T21:39:38.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become\nexercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's\nstockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":35.49,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-035470","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919121035470/doc4.xml","form_type":"4"}},{"id":2757274,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-05T22:40:16.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":70881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted. If employment is terminated prior to the end of the calendar quarter in which the option was granted, the number of shares underlying such stock\noption that reflects the percentage of calendar days remaining in such calendar quarter after such employment termination date shall be forfeited and deemed cancelled."}],"balance_after":70881,"derivative":{"exercise_price":3.05,"exercise_date":"2021-04-01","expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":70881},"source":{"system":"sec-edgar","filing":"0001192482-21-000303","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248221000303/edgar.xml","form_type":"4"}},{"id":2891956,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T21:08:08.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date."}],"balance_after":850000,"derivative":{"exercise_price":3.32,"expiration_date":"2031-01-26","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001192482-21-000119","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248221000119/edgar.xml","form_type":"4"}},{"id":2915050,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-06T21:47:20.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":64798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":64798,"derivative":{"exercise_price":2.64,"exercise_date":"2021-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":64798},"source":{"system":"sec-edgar","filing":"0001192482-21-000047","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248221000047/edgar.xml","form_type":"4"}},{"id":3015755,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-02T20:02:16.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":76674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":76674,"derivative":{"exercise_price":2.24,"exercise_date":"2020-10-01","expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":76674},"source":{"system":"sec-edgar","filing":"0001192482-20-000761","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248220000761/edgar.xml","form_type":"4"}},{"id":3088472,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-06T20:28:44.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":64683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":64683,"derivative":{"exercise_price":2.56,"exercise_date":"2020-07-01","expiration_date":"2030-07-01","underlying":"Common Stock","underlying_shares":64683},"source":{"system":"sec-edgar","filing":"0001192482-20-000604","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248220000604/edgar.xml","form_type":"4"}},{"id":3102929,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T20:05:17.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":84322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":84322,"derivative":{"exercise_price":2.51,"exercise_date":"2020-06-18","expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":84322},"source":{"system":"sec-edgar","filing":"0001192482-20-000554","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248220000554/edgar.xml","form_type":"4"}},{"id":3113126,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-06-12T00:28:44.000Z","date":"2020-06-09","kind":"purchase","acquired":true,"shares":100000,"price":2.5,"value":250000.0,"ownership":{"direct":true},"balance_after":175746,"source":{"system":"sec-edgar","filing":"0001192482-20-000477","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000119248220000477/edgar.xml","form_type":"4"}},{"id":3113125,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T20:18:05.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":36.47,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-004426","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218020004426/primarydocument.xml","form_type":"4"}},{"id":3113669,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-06-11T20:15:41.000Z","date":"2020-06-09","kind":"purchase","acquired":true,"shares":100000,"price":2.5,"value":250000.0,"ownership":{"direct":true},"balance_after":175746,"source":{"system":"sec-edgar","filing":"0001192482-20-000475","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000475/edgar.xml","form_type":"4"}},{"id":3136804,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-05-22T21:01:10.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Michael Cola continuing in service on the Board through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":36.85,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-031794","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919120031794/doc4.xml","form_type":"4"}},{"id":3288382,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-05T21:38:52.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments, subject to the reporting person's continued service on each such vesting date."}],"balance_after":1200000,"derivative":{"exercise_price":3.98,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001104659-20-011268","document":"tm206826d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000110465920011268/tm206826d3_4.xml","form_type":"4"}},{"id":3288381,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-02-05T21:38:52.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":75746,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 2,267,859 shares of Aevi Genomic Medicine, Inc. (\"Aevi\") common stock in connection with the merger of Aevi into a wholly owned subsidiary of the issuer pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Aevi, Genie Merger Sub, Inc., Second Merger Sub, LLC and the issuer."}],"balance_after":75746,"source":{"system":"sec-edgar","filing":"0001104659-20-011268","document":"tm206826d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000110465920011268/tm206826d3_4.xml","form_type":"4"}},{"id":3289091,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":21181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5,\n2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock\nbeing issued and the warrant was rendered null and void."}],"balance_after":0,"derivative":{"exercise_price":2.84,"expiration_date":"2022-10-17","underlying":"Common Stock","underlying_shares":21181},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289090,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":4.22,"expiration_date":"2023-09-13","underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289089,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option, which became exercisable on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289088,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":661000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":661000},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289087,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger"}],"balance_after":0,"derivative":{"exercise_price":1.51,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289086,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger"}],"balance_after":0,"derivative":{"exercise_price":4.91,"expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289085,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger"}],"balance_after":0,"derivative":{"exercise_price":4.83,"expiration_date":"2026-04-15","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289084,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":292087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which became exercisable on February 18, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger"}],"balance_after":0,"derivative":{"exercise_price":7.01,"expiration_date":"2025-02-18","underlying":"Common Stock","underlying_shares":292087},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289083,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":17327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":6.45,"expiration_date":"2024-04-16","underlying":"Common Stock","underlying_shares":17327},"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3289082,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-05T16:13:47.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":2267859,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. (\"Cerecor\"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the \"Merger\").  At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001192482-20-000111","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000111/edgar.xml","form_type":"4"}},{"id":3348349,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-12-09T21:15:37.000Z","date":"2019-12-05","kind":"purchase","acquired":true,"shares":2049376,"price":0.134,"value":274616.384,"ownership":{"direct":true},"balance_after":2267859,"source":{"system":"sec-edgar","filing":"0001192482-19-000513","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248219000513/edgar.xml","form_type":"4"}},{"id":3487484,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T21:02:14.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":10000,"derivative":{"exercise_price":15.04,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-037410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919119037410/doc4.xml","form_type":"4"}},{"id":3487483,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T21:02:14.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU).  100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-19-037410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919119037410/doc4.xml","form_type":"4"}},{"id":3498596,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T20:02:21.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":177.41,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-19-003390","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218019003390/primarydocument.xml","form_type":"4"}},{"id":3890957,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-06-18T16:27:34.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":661000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":661000,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":661000},"source":{"system":"sec-edgar","filing":"0001192482-18-000304","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000304/edgar.xml","form_type":"4"}},{"id":3892247,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-15T20:32:08.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":10000,"derivative":{"exercise_price":18.3,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-18-016772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000089924318016772/doc4.xml","form_type":"4"}},{"id":3892246,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-15T20:32:08.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-18-016772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000089924318016772/doc4.xml","form_type":"4"}},{"id":3899722,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-08T20:03:26.000Z","date":"2018-06-06","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 6, 2019 or the day immediately prior to the 2019 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":154.06,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-18-002926","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218018002926/primarydocument.xml","form_type":"4"}},{"id":3931156,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-05-16T16:35:16.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on May 14, 2019, then in 24 equal monthly installments on the 14th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":450000,"derivative":{"exercise_price":1.51,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001192482-18-000223","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000223/edgar.xml","form_type":"4"}},{"id":3931157,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-05-16T16:27:00.000Z","date":"2017-08-11","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."}],"balance_after":50000,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001192482-18-000222","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000222/edgar.xml","form_type":"4/A","original_submission_date":"2017-08-15"}},{"id":4184120,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Warrant (right to buy)","published_at":"2017-10-18T16:17:44.000Z","date":"2017-10-17","kind":"purchase","acquired":true,"shares":21181,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21181,"derivative":{"exercise_price":2.84,"exercise_date":"2017-10-17","expiration_date":"2022-10-17","underlying":"Common Stock","underlying_shares":21181},"source":{"system":"sec-edgar","filing":"0001144204-17-053032","document":"tv477171_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417053032/tv477171_4.xml","form_type":"4"}},{"id":4184119,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-10-18T16:17:44.000Z","date":"2017-10-17","kind":"purchase","acquired":true,"shares":119047,"price":1.26,"value":149999.22,"ownership":{"direct":true},"balance_after":218483,"source":{"system":"sec-edgar","filing":"0001144204-17-053032","document":"tv477171_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417053032/tv477171_4.xml","form_type":"4"}},{"id":4234123,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2017-08-15T16:15:56.000Z","date":"2017-08-11","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":500000,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001144204-17-043507","document":"v473385_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417043507/v473385_form4.xml","form_type":"4"}},{"id":4277209,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-19T21:06:26.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":10000,"derivative":{"exercise_price":13.75,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-040878","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919117040878/doc4.xml","form_type":"4"}},{"id":4277208,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-19T21:06:26.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU).  100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-17-040878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000120919117040878/doc4.xml","form_type":"4"}},{"id":4288156,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-08T23:37:59.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 7, 2018 or the day immediately prior to the 2018 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":14000,"derivative":{"exercise_price":72.74,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001562180-17-002237","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1188940/000156218017002237/primarydocument.xml","form_type":"4"}},{"id":4439875,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":45168,"kind":"person","name":"COLA MICHAEL F","position":1,"cik":"0001188940","reported_name":"COLA MICHAEL F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Purchase)","published_at":"2017-02-17T17:44:54.000Z","date":"2017-02-17","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable in three equal installments (rounded up to the nearest whole share of common stock) on February 17, 2018, February 17, 2019 and February 17, 2020, subject to the reporting person's continued service with the issuer."}],"balance_after":250000,"derivative":{"exercise_price":4.91,"expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001192482-17-000047","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248217000047/edgar.xml","form_type":"4"}}]}